指南与共识神经肿瘤

成人胶质母细胞瘤:神经肿瘤学会(SNO)与欧洲神经肿瘤学会(EANO)关于当前管理与未来方向的共识综述

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
指南 / 共识 · Neuro Oncol · 2020-01-01

胶质母细胞瘤是最常见的恶性原发性脑肿瘤,是重要的致病和致死原因。近年对其分子发病机制和生物学的认识有重要进展,但未转化为患者结局的显著改善。本共识综述讨论异柠檬酸脱氢酶野生型(IDHwt)胶质母细胞瘤的当前管理,并回顾靶向分子治疗、DNA损伤反应与代谢靶向药物、免疫治疗和病毒治疗等新疗法及研究挑战与未来方向。

要点

  • 胶质母细胞瘤是最常见的恶性原发性脑肿瘤,是重要致病和致死原因。
  • 分子发病机制和生物学认识有重要进展,但未转化为患者结局的显著改善。
  • 本共识综述讨论IDHwt胶质母细胞瘤当前管理,并回顾靶向、免疫和病毒治疗等新疗法。

核心结论

  • 近年对胶质母细胞瘤分子发病机制和生物学的认识有重要进展,但未转化为患者结局的显著改善。

研究设计与样本

  • 本共识综述由神经肿瘤学会(SNO)与欧洲神经肿瘤学会(EANO)发布,讨论成人IDHwt胶质母细胞瘤的当前管理,并回顾靶向分子治疗、DNA损伤反应与代谢靶向药物、免疫治疗和病毒治疗等新疗法及研究挑战与未来方向。

主要发现

  • 胶质母细胞瘤是最常见的恶性原发性脑肿瘤,是重要的致病和致死原因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020. PMID: 32328653. doi:10.1093/neuonc/noaa106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。